BMS and Medarex sign an anticancer deal
In a multi-year agreement, Medarex and Bristol-Myers Squibb will co-develop Medarex's fully human antibody MDX-010 to treat various types of cancer and other diseases. The deal also covers Medarex's MDX-1379, a melanoma peptide vaccine in Phase III development as an adjunct therapy to MDX-010.
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.